

**S1 Table.** Quality of the 14 selected studies based on the assessment with the Newcastle-Ottawa-Scale [1-13]

Study	Selection				Comparability	Outcome			Total No. of stars
	Representativeness of the exposed cohort	Selection of the Non-Exposed Cohort	Ascertainment of exposure	Outcome of interest		Assessment of outcome	Length of follow-up	Adequacy of follow-up	
Dell'Acqua 2019	*	.	*	*	.	*	.	*	5
Jingu 2017	*	.	*	*	.	*	*	*	6
Kinj 2017	*	.	*	*	.	*	*	*	6
Agolli 2016	*	.	*	*	.	*	*	*	6
Aoki 2016	*	.	*	*	.	*	*	*	6
Binkley 2015	*	.	*	*	.	*	.	*	5
Carvajal 2015	*	.	*	*	.	*	.	*	5
Filippi 2015	*	.	*	*	.	*	.	*	5
Jung 2015	*	.	*	*	.	*	*	*	6
Comito 2014	*	.	*	*	.	*	.	*	5
Navarria 2014	*	.	*	*	.	*	.	*	5
Bae 2012	*	.	*	*	.	*	*	*	6
Takeda 2011	*	.	*	*	.	*	*	*	6
Kim 2009	*	.	*	*	.	*	*	*	6

\*This study has met the criteria for a domain of the Newcastle-Ottawa-Scale.

## References

1. Dell'Acqua V, Surgo A, Kraja F, Kobiela J, Zerella MA, Spsychalski P, et al. Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions. *Clin Exp Metastasis*. 2019;36:331-42.

2. Jingu K, Matsuo Y, Onishi H, Yamamoto T, Aoki M, Murakami Y, et al. Dose escalation improves outcome in stereotactic body radiotherapy for pulmonary oligometastases from colorectal cancer. *Anticancer Res.* 2017;37:2709-13.
3. Kinj R, Bondiau PY, Francois E, Gerard JP, Naghavi AO, Leysalle A, et al. Radiosensitivity of colon and rectal lung oligometastasis treated with stereotactic ablative radiotherapy. *Clin Colorectal Cancer.* 2017;16:e211-20.
4. Agolli L, Bracci S, Nicosia L, Valeriani M, De Sanctis V, Osti MF. Lung metastases treated with stereotactic ablative radiation therapy in oligometastatic colorectal cancer patients: outcomes and prognostic factors after long-term follow-up. *Clin Colorectal Cancer.* 2017;16:58-64.
5. Aoki M, Hatayama Y, Kawaguchi H, Hirose K, Sato M, Akimoto H, et al. Stereotactic body radiotherapy for lung metastases as oligo-recurrence: a single institutional study. *J Radiat Res.* 2016;57:55-61.
6. Binkley MS, Trakul N, Jacobs LR, von Eyben R, Le QT, Maxim PG, et al. Colorectal histology is associated with an increased risk of local failure in lung metastases treated with stereotactic ablative radiation therapy. *Int J Radiat Oncol Biol Phys.* 2015;92:1044-52.
7. Carvajal C, Navarro-Martin A, Cacicedo J, Ramos R, Guedea F. Stereotactic body radiotherapy for colorectal lung oligometastases: preliminary single-institution results. *J BUON.* 2015;20:158-65.
8. Filippi AR, Badellino S, Ceccarelli M, Guarneri A, Franco P, Monagheddu C, et al. Stereotactic ablative radiation therapy as first local therapy for lung oligometastases from colorectal cancer: a single-institution cohort study. *Int J Radiat Oncol Biol Phys.* 2015;91:524-9.
9. Jung J, Song SY, Kim JH, Yu CS, Kim JC, Kim TW, et al. Clinical efficacy of stereotactic ablative radiotherapy for lung metastases arising from colorectal cancer. *Radiat Oncol.* 2015;10:238.
10. Comito T, Cozzi L, Clerici E, Campisi MC, Liardo RL, Navarria P, et al. Stereotactic ablative radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. *BMC Cancer.* 2014;14:619.
11. Navarria P, Ascolese AM, Tomatis S, Cozzi L, De Rose F, Mancosu P, et al. Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments. *Radiat Oncol.* 2014;9:91.
12. Bae SH, Kim MS, Cho CK, Kang JK, Kang HJ, Kim YH, et al. High dose stereotactic body radiotherapy using three fractions for colorectal oligometastases. *J Surg Oncol.* 2012;106:138-43.

13. Takeda A, Kunieda E, Ohashi T, Aoki Y, Koike N, Takeda T. Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. *Radiother Oncol.* 2011;101:255-9.